Showing results (331-340 of 399) with videos related to

Sort By:
Pageof 40
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 6, 2019
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1Mohamad Yasmin, Derrick E Fouts, Michael R Jacobs, et al.
Circulation|January 26, 1999
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heartN Bowling, R A Walsh, G Song, et al.
Rural Mental Health|September 25, 2025
Sociodemographic Factors and Mental Health in Health Care Professionals and Patients During COVID-19Anna K Radin, Zihan Zheng, Jenny Shaw, et al.
The Journal of Infectious Diseases|April 1, 1994
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humansC Gonzalez, D Hone, F R Noriega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
Virology|February 20, 2007
Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesVidita Choudhry, Mei-Yun Zhang, Igor A Sidorov, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2018
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and <i>Enterobacteriaceae</i> with Defined Extended-Spectrum β-Lactamases and CarbapenemasesMichael R Jacobs, Ayman M Abdelhamed, Caryn E Good, et al.
Frontiers in Pharmacology|September 15, 2022
Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in miceDavid L Goldblatt, Gabriella Valverde Ha, Shradha Wali, et al.
Gastroenterology|September 21, 2014
Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in micePeng Chen, Manolito Torralba, Justin Tan, et al.
Pageof 40